| Date Filed | Type | Description |
| 10/06/2023 |
SC 13D/A
| Oaktree Capital Group, LLC reports a 7.8% stake in IMPEL PHARMACEUTICALS INC. |
| 10/05/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 10/04/2023 |
8-K
| Credit agreement amendment |
| 08/21/2023 |
8-K
| Credit agreement amendment |
| 08/18/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/15/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 06/16/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/12/2023 |
4
| Kalb Michael Wayne (CFO) has filed a Form 4 on IMPEL PHARMACEUTICALS INC|
Txns:
| Granted 175,000 options to buy
@ $2.43, valued at
$425.3k
Granted 47,500 options to buy
@ $0 |
|
| 05/12/2023 |
3
| Kalb Michael Wayne (CFO) has filed a Form 3 on IMPEL PHARMACEUTICALS INC |
| 05/12/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/12/2023 |
8-K
| Quarterly results |
| 05/10/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/17/2023 |
8-K
| Quarterly results |
| 04/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/14/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/13/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 03/31/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/31/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 03/27/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/27/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/24/2023 |
8-K
| Quarterly results |
| 03/10/2023 |
3
| Amin Rajiv (VP, Controller & Interim CFO) has filed a Form 3 on IMPEL PHARMACEUTICALS INC |
| 01/09/2023 |
8-K
| Quarterly results |
| 01/04/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/14/2022 |
8-K
| Quarterly results |
| 08/15/2022 |
8-K
| Quarterly results |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/17/2022 |
4
| SHAH MAHENDRA (Director) has filed a Form 4 on IMPEL PHARMACEUTICALS INC|
Txns:
| Granted 12,789 options to buy
@ $8.65, valued at
$110.6k
|
|
|